aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Avalyn Pharma Inc., founded with a mission to develop innovative therapies for rare respiratory diseases, focuses primarily on Idiopathic Pulmonary Fibrosis (IPF). The company aims to improve the quality of life for patients through its specialized inhaled treatments. Avalyn's product pipeline includes several promising candidates such as AP01, AP02, and AP03, all designed to deliver targeted therapy directly to the lungs, enhancing efficacy and reducing systemic side effects.
Notable figures associated with Avalyn Pharma include experienced leaders and board members from the biopharmaceutical industry. The company has attracted significant investment from prominent healthcare investors, enabling it to advance its clinical trials and expand its research capabilities. Avalyn’s key achievements include the successful enrollment of patients in its MIST PPF study and progress in developing multiple inhaled formulations. The impact of Avalyn Pharma lies in its potential to revolutionize treatment for IPF and other rare lung diseases, offering new hope to patients worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Avalyn Pharma founded?
Avalyn Pharma was founded in 2011.
Where is Avalyn Pharma’s headquarters located?
Avalyn Pharma’s headquarters is located in Seattle, US.
When was Avalyn Pharma’s last funding round?
Avalyn Pharma’s most recent funding round was for $175M (USD) in September 2023.
How many employees does Avalyn Pharma have?
Avalyn Pharma has 27 employees as of Feb 5, 2024.
How much has Avalyn Pharma raised to-date?
As of July 05, 2023, Avalyn Pharma has raised a total of $272.5M (USD) since Sep 27, 2023.
Add Comparison
Total Raised to Date
$272.5M
USD
Last Update Sep 27, 2023
Last Deal Details
$175M
USD
Sep 27, 2023
Series C
Total Employees Over Time
27
As of Feb 2024
Avalyn Pharma Address
701 Pike St
suite 1500
Seattle,
98101
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts